Opioids exert many of their acute effects through modulating ion channels via G βγ subunits. Some of their side effects are attributed to β-arrestin recruitment, and several biased agonists that do not activate this pathway have been developed recently. Here we tested the effects of TRV130, PZM21 and herkinorin, three G-protein biased agonists of μ-opioid receptors (μOR), on ion channel targets. Compared to the full μOR agonist DAMGO, all three biased agonists induced smaller activation of G proteincoupled inwardly rectifying potassium channels (GIRK2), and smaller inhibition of Transient Receptor Potential Melastatin (TRPM3) channels. Furthermore, co-application of TRV130 or PZM21, but not herkinorin reduced the effects of DAMGO on both ion channels. Ca V 2.2 was also inhibited less by PZM21 and TRV130 than by DAMGO.
INTRODUCTION
Chronic pain is an unsolved medical problem, causing immense suffering to millions of people worldwide (Basbaum et al., 2009) . Opioids remain the main therapy against severe chronic pain, but these medications cause multiple side effects limiting their application, and are also highly addictive. The lack of better pain control is believed to be a significant driving force behind the opioid addiction crisis (Skolnick and Volkow, 2016 ).
Opioids exert their effects via binding to μ-δ-or κ-opioid receptors (Stein, 2016) . All these receptors act via inhibitory G-proteins in the G αi/o family . Upon receptor activation, the G α subunits dissociate from G βγ , and both subunits activate multiple downstream effectors. Opioid receptor activation also induces recruitment of β-arrestins, leading to receptor desensitization, internalization and various other effects. β-arrestins however, are not only important for desensitization, but they are also emerging as independent signaling mediators regulating various effectors (DeWire et al., 2007) , including ion channels (Liu et al., 2017) . Most clinically useful analgesic effects of opioids are mediated by μ-opioid receptors (μOR). Some side effects of opioids, such as tolerance have been attributed μOR signaling via β-arrestins (Raehal et al., 2011) .
On the cellular level, opioid receptor activation leads to decreased cAMP production, an effect mediated by inhibition of the adenylate cyclase enzyme by G αi. Many acute effects of opioids are mediated by reduction of neuronal activity via modulation of ion channels by G βγ subunits. The two classical actions of G αi/o signaling are activation of G-protein coupled inwardly rectifying K + channels (GIRK) and inhibition of N-and P/Q type voltage gated Ca 2+ channels (Ca v 2.2 and Ca v 2.1) (Clapham and Neer, 1997) , both effects leading to reduced neuronal activity.
We and others recently identified Transient Receptor Potential Melastatin 3 (TRPM3) as a novel ion channel target of G βγ subunits; these channels are robustly inhibited by activation of a variety of G αi -coupled receptors, including μOR in dorsal root ganglion (DRG) neurons, as well as in expression systems (Badheka et al., 2017; Dembla et al., 2017; Quallo et al., 2017) . TRPM3 is a heat-activated Ca 2+ permeable non-selective cation channel; its genetic deletion in mice results in reduced heat sensitivity (Vriens et al., 2011; Vandewauw et al., 2018) . TRPM3 also has chemical activators such as the endogenous neurosteroid Pregnenolone Sulphate (PregS) (Wagner et al., 2008) as well as synthetic chemical activators including CIM0216 and nifedipine (Held et al., 2015) .
This channel is also involved in regulating glucose homeostasis and expressed in many other tissues including pancreatic beta cells, retina and brain (Oberwinkler and Philipp, 2014) .
Several biased agonists of μOR that activate G-protein signaling, but do not lead to β-arrestin recruitment have been recently described with the goal of developing painkillers with reduced side effects. Herkinorin was the first G-protein-biased agonist that was claimed not to lead to β-arrestin recruitment and receptor internalization (Groer et al., 2007) . TRV130 (oliceridine) developed by Trevena pharmaceuticals (DeWire et al., 2007) , has shown promising analgesic effects in clinical trials (Viscusi et al., 2016; Singla et al., 2017) . The latest G-protein biased μOR agonist PZM21 was developed based on structure guided computational modeling, and showed promising analgesic results in mice (Manglik et al., 2016) . The study showed that PZM21 as well as TRV130
did not lead to β-arrestin recruitment, but found that herkinorin evoked β-arrestin recruitment similar to that induced by full agonists (Manglik et al., 2016) . The effects of these G-protein biased agonists have not yet been tested on ion channel targets of G αi signaling.
Here we tested the effects of the G-protein biased μOR agonists TRV130, PZM21 and herkinorin on three ion channel targets of G βγ . Surprisingly we found that all three biased agonists induced significantly smaller inhibition of TRPM3, and Ca V 2.2 voltage gated Ca 2+ channels and smaller activation of GIRK2 than the full agonist DAMGO.
Furthermore, PZM21 and TRV130, but not herkinorin relieved DAMGO-induced inhibition of TRPM3, and reduced DAMGO-induced activation of GIRK2 channels. All three G-protein biased agonists were less efficient in inducing G-protein dissociation than DAMGO. Overall our data indicate that PZM21 and TRV130 act as partial μOR agonists.
RESULTS

G-protein biased μOR agonists inhibit TRPM3 channels less than the full agonist DAMGO
The initial motivation of this study was to test the potential involvement of the β-arrestin pathway in the inhibition of TRPM3 channels. To this end, first we tested the effects of PZM21, TRV130 and Herkinorin on Ca 2+ signals induced by the TRPM3 agonist PregS in DRG neurons. We have found that the full μOR agonist DAMGO (1 μM) induced strong inhibition in the vast majority of the PregS responsive neurons (61 of 64; 95%) ( Fig. 1A) , while application of the other three agonists at the same concentration affected only a much smaller fraction of the PregS responsive neurons (Fig 1B-C) . For 1 μM Herkinorin we observed inhibition in 38 out of 69 (55 %) tested neurons (Fig. 1B) , for 1 μM PZM21 in 14 out of 22 (63 %) (Fig. 1C) , and for 1 μM TRV130 in 12 out of 22 neurons (54 %) (Fig. 1D ). We also observed that the inhibitory effects of these three biased agonists were longer lasting compared to the quickly reversible effects of DAMGO.
DRG neurons express all three types of opioid receptors -μ, δ, κ, which may potentially confound interpretation of these data, as some of the μOR agonists may cross-react with other opioid receptors. Therefore we co-expressed μOR and TRPM3 channels in HEK cells and performed Ca 2+ imaging experiments similar to those in DRG neurons.
We found that similar to DRG neurons, PZM1, TRV130 and herkinorin evoked significantly smaller inhibition of PregS-induced Ca 2+ signals than DAMGO (Fig 2) . (Fig. 3) . In these experiments we tested two concentrations for each agonist 100 nM and 1 μM. In each measurement, we applied two pulses of 25 μM PregS; during the first application we also applied the tested agonist and during the second one we applied DAMGO as a control. In all cases application of DAMGO, both 100 nM and 1 μM produced almost full inhibition of both inward (-100 mV) and outward TRPM3 currents (+100 mV). For the three tested substances the inhibitory effects were smaller compared to DAMGO. For 100 nM PZM21, PregS-induced currents were inhibited by 43.4±3.3 % (p=0.0001) at +100 mV and 50.1±8.5 % (p=0.0037) at -100 mV. In the same experiments, 100 nM DAMGO inhibited TRPM3 currents by 79.7±10 % (p<0.00001) for the outward and 72.8±12.9 % (p=0.00011) for the inward currents, n=6 (Fig. 3A ). PZM21 at 1 μM induced a more pronounced inhibition 64.9±10.2 % (p<0.00001) for the outward and 62.2±10.8 % (p<0.00001) for the inward currents. In the same experiments 100 nM DAMGO inhibited currents by 93.2±4.5 % (p<0.00001) for the outward and 86.6±1.6 % (p<0.00001) for the inward (-100 mV) currents, n=6 (Fig. 3B) . Application of 100 nM Herkinorin had minor effects on PregS-induced currents both at +100 mV, evoking 21.1±5 % inhibition (p=0.015) and -100 mV 31±11.2 % 37 % inhibition (p=0.025), while the identical concentration of DAMGO induced 75.2±5.4 % inhibition (p=0.00002) for +100 mV and 71.7±4.4 % (p<0.00001) for -100 mV in the same experiments, n=5 (Fig. 3C ).
Application of 1 μM Herkinorin had a more pronounced inhibitory effect and lead to 6 current inhibition 53.7±11 % (p=0.00027) for the outward current and 58.8±14 % (p=0.0017) for the inward current. In the same experiments 1 μM DAMGO lead to current inhibition by 89.1±3 % (p<0.00001) for the outward and 83.2±3.9 % (p=0.00007)
for the inward currents, n=5 (Fig. 3D ). TRV130 behaved similarly; at 100 nM it decreased TRPM3 currents by 45.6±12 % (p=0.0029) for +100 mV and by 48.2±12.8 % (p=0.0019) for -100 mV, compared to 100 nM DAMGO, which inhibited currents by 84.2±6.5 % (p<0.00001) for +100 mV and by 76.9±4.9 % (p<0.00001) for -100 mV, n=6
( Fig. 3E) Fig. 3H ).
PZM21 and TRV130 relieve DAMGO-induced inhibition of TRPM3 currents
To test if these new reagents behave as partial agonists we performed patch clamp recordings where TRPM3 was first inhibited by 100 nM DAMGO, then PZM21 or TRV130, was co-applied with DAMGO (Fig 4) . We found that 100 nM DAMGO inhibited PregS-induced currents by 97.5±3.2 % for the outward (+100 mV) and 94.9±2.8 % for the inward (-100 mV) currents. When 1 μM PZM21 was co-applied with DAMGO, TRPM3 currents recovered substantially up to 32.7±7.5 % inhibition (p<0.00001 vs.
DAMGO inhibition) for the outward (+100 mV) and 33.3 ±8.9 % (p=0.0001 vs. DAMGO inhibition) for the inward (-100 mV) currents, n=9 (Fig. 4A,B) . When PZM21 was washed out in the continuous presence of DAMGO, currents returned to close to baseline again (Fig. 4A,B ).
Similar effects were observed also for 1 μM TRV130 (Fig. 4C,D) . In these experiments DAMGO inhibited PregS-induced currents by 96.8±3.7 % for +100 mV and 88.4±2.2 % for -100 mV, and TRV130 reversed this inhibition to 3.9±7.5 % potentiation (p<0.00001 vs. DAMGO inhibition) at +100 mV and 7.2±11.4 % potentiation (p<0.00001 vs.
DAMGO inhibition) at -100 mV, n=7. As opposed to the effect of PZM21, the effect of TRV130 was not quickly reversible (Fig. 4C ).
As opposed to PZM21 and TRV130, application of 1 μM herkinorin did not induce a robust recovery from DAMGO-induced inhibition (Fig. 4 E,F) . In this set of experiments we observed that 100 nM DAMGO inhibited PregS-induced currents by 81.2±5.6% at +100 mV; after co-application of herkinorin, inhibition decreased to 61.5±7.4%, but this effect was not statistically significant (p=0.63 vs. DAMGO inhibition). At -100 mV DAMGO induced an 81.4±7.2% inhibition, which decreased to 62.8±8.4% after the coapplication of herkinorin (p=0.77 vs. DAMGO inhibition, n=10).
As a control we co-applied 1 μM DAMGO in the presence of 100 nM DAMGO which slightly, but not statistically significantly increased the initial inhibitory level (Gig. 4G,H).
After the initial 100 nM DAMGO application outward currents were inhibited by To test the possibility of the partial agonist behavior of PZM21, TRV130 and Herkinorin we co-applied them with DAMGO. After strong DAMGO activation of GIRK2 channels, PZM21 and TRV130 quickly induced significant and prominent reduction of the potassium current amplitude, while Herkinorin did not have a clear inhibitory effect (Fig. 6 ). In control experiments the application of 1 μM DAMGO slightly potentiated the effect of 100 nM DAMGO (Fig 6) . GIRK2 currents induced by 100 nM DAMGO were inhibited upon the application 100 nM PZM21 by 52.6±7.9% (p<0.00001, n=5) and for 1 μM PZM21 GIRK currents were inhibited by 71.4±5.4 % (p<0.00001, n=7). TRV130 (100 nM) inhibited GIRK currents by 51.4±4.6 % (p<0.00001, n=6) and 1 μM TRV130 reduced DAMGO-induced GRIK currents by 73.4±4.8 % (p<0.00001, n=8).
Herkinorin at 1 μM resulted in a current decrease corresponding to 7.2±7.0 % inhibition (p=0.38), n=4, but the currents showed substantial desensitization, therefore this small decrease may not be due to herkinorin (Fig. 6C ). To account for this spontaneous current decrease, inhibition levels were calculated by taking the average of GIRK currents before and after application of the test compounds as the control level for all tested compounds. In a control experiment application of 1 μM DAMGO on top of 100 nM DAMGO lead to a slight potentiation 5.0±3.1 % (p=0.49), n=6 ( Fig. 6D ). Morphine (1 μM) did not induce a significant inhibition of DAMGO-induced GIRK currents (Fig. 6E ). Our data show that G-protein biased μOR agonists were less efficient than the full agonist DAMGO in modulating three different ion channel targets to G αi -G βγ signaling.
G-protein biased
We next tested if the G-protein biased agonists were also less efficient than DAMGO on G-protein dissociation, using a FRET-based assay.
G-protein μOR biased agonists are less efficient than DAMGO in inducing Gprotein dissociation
To assess the dissociation level of G α and G βγ during μOR activation we used a FRET- (1.58±0.41 % decrease, p=0.0017, n=8), 1 μM TRV130 (1.03±0.17 % decrease, p=0.00013, n=6) and 1 μM herkinorin (1.52±0.32 % decrease, p<0.00001, n=5). These data indicate a smaller level of dissociation of G αi1 and G βγ compared to the effect of the full μOR agonist DAMGO by these agonists. As 1 μM herkinorin did not evoke a clear reversal of DAMGO-induced inhibition of TRPM3 and DAMGO-induced activation of GIRK, we also tested higher concentrations of this drug in the FRET assay. For 10 μM herkinorin we observed 0.88±0.14 % of FRET signal decrease (p<0.0018, n=8) an effect very similar to that induced by 1 μM herkinorin. The effects of PZM21, TRV130 and herkinorin were significantly smaller than that induced by 1 μM DAMGO (Fig. 8C) .
In conclusion we demonstrate that the recently described G αi -biased agonists PZM21
and TRV130 behave as weak partial agonists using three ion channel targets for the G βγ subunits as a functional readout.
DISCUSSION
Most available opioid medications activate the G αi -coupled μOR-s; ligand binding to these receptors leads to the dissociation of G α and G βγ and also induces β-arrestin recruitment. Both G-protein subunits have their own effectors; G αi inhibits adenylate cyclase (AC), and thus decrease cAMP level. G βγ subunits have multiple targets including G protein-coupled inwardly-rectifying potassium channels (Kir3) (Logothetis et al., 1987) and voltage-gated Ca 2+ channels (N-type and P/Q-type) (Currie, 2010) . A recently described target of G i -signaling is the TRPM3 ion channel, which is robustly inhibited by G βγ subunits (Badheka et al., 2017; Dembla et al., 2017; Quallo et al., 2017) . Non-ion channel targets of G βγ include phosphoinositide 3-kinase-γ (PI3Kγ) and mitogen-activated protein kinases (Khan et al., 2013) , (Clapham and Neer, 1997) .
β-arrestin 1 (arrestin 2) and β-arrestin 2 (arrestin 3) are important regulators of Gprotein signaling. They were originally described as mediators of agonist-induced desensitization and internalization (DeWire et al., 2007) , and they were presumed to be responsible for many side effects of opioids, such as tolerance and respiratory depression. Recently β-arrestins have emerged as independent signaling mediators regulating various effectors (DeWire et al., 2007) , including ion channels in the TRP family (Liu et al., 2017) . We initiated this study to determine the possible role of the β-arrestin pathway in regulating TRPM3 channels, the newly described targets of G βγ signaling.
We found that all three G-protein biased μOR agonists, PZM21, TRV130 and Herkinorin induced significantly smaller inhibition of TRPM3 channels compared to the full agonist DAMGO both in Ca 2+ imaging and patch-clamp experiments. PZM21 and TRV130 also reversed the inhibitory effect of DAMGO when co-applied with this full agonist. These results may indicate the involvement of the β-arrestin pathway in TRPM3 regulation.
Initially designed as control experiments, we also found that all these reagents induced a weaker GIRK channel activation than DAMGO. Similar to TRPM3 channels, PZM21
and TRV130, but not herkinorin robustly opposed the effect on DAMGO on GIRK channels when co-applied with this full agonist. Voltage gated Ca V 2.2 channels were also inhibited less by PZM21 and TRV130 compared to DAMGO. These results could indicate two possibilities; either the β-arrestin pathway is required for the activation of all three ion-channel targets of Gβγ, or PZM21, TRV130 and herkinorin act as partial agonists in G-protein signaling. To differentiate between these two possibilities, we reexamined the effects of these compounds on G-protein dissociation. We performed FRET experiments and found that all tested reagents induced weaker G α -G βγ dissociation than DAMGO, indicating that PZM21 and TRV130 behave as weak partial agonists when regulating ion channel targets for G βγ subunits.
All three compounds tested here were developed as G-protein biased μOR agonist to avoid recruitment of β-arrestin with the promise of novel pain medications with fewer side effects. Herkinorin demonstrated strong antinociceptive effects, similar to that of morphine, in several behavioral assays without inducing tolerance (Lamb et al., 2012) .
At the cellular level it was demonstrated that herkinorin did not recruit β-arrestin 2 and did not promote internalization, but had G α agonist activity similar, or stronger than that of DAMGO, detected by a MAP kinase phosphorylation assay (Groer et al., 2007) .
TRV130 was also shown to be effective in a variety of behavioral tests with efficacy and potency similar to that of morphine, while inducing less constipation and respiratory suppression compared to similar doses of morphine (DeWire et al., 2013) . As a biased agonist it strongly activated G αi (cAMP assay) without recruitment of β-arrestin 2 (enzyme complementation assay) (DeWire et al., 2013) . These findings were confirmed by another independent study on TRV130 (Mori et al., 2017) .
The newest G αi -biased μOR agonist PZM21 was identified based on computational docking of over 3 million compounds to the structure of μOR, and subsequent structure based optimization (Manglik et al., 2016) . PZM21 is structurally unrelated to known opioids; it was shown to induce G-protein activation using various high throughput optical assays, but it induced no recruitment of β-arrestin 2, with very low level of receptor internalization. In behavioral experiments, PZM21 had antinociceptive properties in multiple animal tests with significantly less adverse side effects than known opioids (Manglik et al., 2016) . Manglik et al also compared herkinorin and TRV130 to the effects of PZM21, DAMGO as well as morphine is several high throughput cellular assays. They concluded that PZM21 is a G-protein biased, potent, selective, and efficacious μOR agonist; TRV130 behaved similar to PZM21, but they found that herkinorin induced substantial β-arrestin recruitment.
What is the explanation of the difference between our data and those of Manglik et al?
One possible explanation is that the different assays used to assess G-protein activity
13
have different sensitivities and dynamic ranges. The high throughput optical assays, such as glosensor are not linear readouts of cAMP levels, and while the assay is highly sensitive at low levels of activity, it is possible that at high activities such that induced by DAMGO it may saturate, which could overestimate the maximal effect of a weaker agonist. Indeed while PZM21 was designated as efficacious in G-protein stimulation, it induced between 70 % and ~100 % of the effect of DAMGO depending on the assay (Manglik et al., 2016) . Ionic currents measured in patch clamp experiments on the other hand, are linear readouts of channel activity, which do not saturate, thus this technique is more sensitive at high activity levels.
In our FRET-based G-protein dissociation experiments all three agonists induced well below 50% of the signal induced by DAMGO. In our ion channel experiments, the difference between DAMGO and the biased agonists were variable; depending on the channel, and the concentrations used, but it was again, generally well below the effect induced by DAMGO. We used 100 nM and 1 μM for all compounds; 1 μM was a saturating concentration for all agonists, whereas 100 nM induced maximal or close to maximal responses in most assays (Manglik et al., 2016) . Our most definitive data showing that these compounds act as partial agonists is the clear reversal of the effect of DAMGO on TRPM3 and GIRK channels by PZM21 and TRV130 (Figs. 4 and 6 ).
Herkinorin at 100 nM or 1 µM did not induce a robust reversal of the effect of DAMGO on TRPM3 currents (Fig. 4) and on GIRK channels (Fig. 6 ), but the marked desensitization of both currents makes a small effect difficult to assess. Because of this ambiguity, we also tested the effect of 10 μM herkinorin in our FRET based assay, and its effect was indistinguishable from that induced by 1 μM herkinorin. It is not clear why herkinorin behaves differently from PZM21 and TRV130 in reversing the effects of DAMGO, but we have not further investigated this difference.
Our observations are in line with a recent publication showing that PZM21 acts as a partial agonist with substantially lower efficacy than DAMGO, using a BRET-based assay to detect the dissociation of G αi1 and G γ2 (Hill et al., 2018) . Using the same assay they also found that morphine had a higher efficacy than PZM21, but lower than that of DAMGO (Hill et al., 2018) . Our data are also compatible with another recent publication using a conformational biosensor binding to the purified μOR showing that PZM21 acted as a partial agonist, with lower efficacy than morphine, or phentanyl, two clinically used opiods (Livingston et al., 2018) .
In conclusion, our data indicate that the G-protein biased PZM21 and TRV130 act as weak partial μOR agonists, when signaling to ion channel targets.
METHODS
DRG neuron isolation and culture
Animal procedures were approved by the Institutional Animal Care and Use Committee at Rutgers New Jersey Medical School. DRG neurons were isolated from adult mice of either sex (2-4 months old) using the slightly modified protocol based on (Malin et al., 2007) , as described previously (Lukacs et al., 2007; Yudin et al., 2016) . Briefly, anesthetized animals were perfused via the left ventricle with ice-cold Hank's buffered salt solution (HBSS; Invitrogen) followed by decapitation. DRGs were collected from all spinal segments after laminectomy and maintained in ice-cold HBSS during the isolation. After isolation and trimming of dorsal and ventral roots, ganglia were incubated in an HBSS-based enzyme solution containing 2 mg/ml type I collagenase (Worthington) and 5 mg/ml Dispase (Sigma) at 37°C for 25-30 min, followed by repetitive trituration for dissociation. After centrifugation at 80 × g for 10 min, cells were resuspended and plated on round coverslips pre-coated with poly-l-lysine (Invitrogen) and laminin (Sigma), allowed to adhere for 1 hr and maintained in culture in DMEM/F12
supplemented with 10% FBS (Thermo Scientific), 100 IU/ml penicillin and 100 μg/ml streptomycin and were kept in a humidity-controlled tissue-culture incubator with 5% CO 2 at 37°C for 12-36 hr. before experiments. supplemented with 10% (v/v) fetal bovine serum (FBS), 100 IU/ml penicillin and 100 μg/ml streptomycin in an incubator (37°C in 5% CO 2 ).
HEK293 cells maintenance.
Human Embryonic Kidney 293 (HEK293) cells were purchased from American
Ca
2+ imaging
Ca 2+ imaging measurements were performed with an Olympus IX-51 inverted microscope equipped with a DeltaRAM excitation light source (Photon Technology
International, Horiba), as described earlier (Lukacs et al., 2013) . Briefly, DRG neurons or HEK cells were loaded with 1 μM fura-2 AM (Invitrogen) at 37°C for 40-50 min before the measurement, and dual-excitation images at 340 and 380 nm excitation wavelengths were detected at 510 nm with a Roper Cool-Snap digital CCD camera.
Measurements were conducted in the same bath solution we used for whole-cell patch clamp recording of TRPM3 channels. Raw data analysis was performed using the Image Master software (PTI). We calculated the normalized change in the relative 340/380 ratio, according to the following formula: ΔR n / ΔR 1 = 100(R n − R 0 )/ (R 1 − R 0 ), where R n is the maximum amplitude during application of agonist (n=1 for the first PregS pulse and n=2 for the second PregS pulse) and R 0 is the basal level of fluorescence ratio before stimulation.
TRPM3 channel electrophysiology
Whole-cell patch clamp measurements were performed as described earlier . The cells were transiently transfected with cDNA encoding the mouse TRPMα2 137 NaCl, 5 KCl, 1 MgCl 2 , 2 CaCl 2 , 10 HEPES and 10 glucose, pH 7.4. The intracellular solution contained (in mM) 140 potassium gluconate, 5 EGTA, 1 MgCl 2 , 10 HEPES, and 2 NaATP, pH 7.3. Patch clamp pipettes were prepared from borosilicate glass capillaries (Sutter Instruments) using a P-97 pipette puller (Sutter Instrument) and had a resistance of 4-6 MΩ. In all experiments after formation of gigaohm-resistance seals, the whole-cell configuration was established and currents were recorded using a ramp protocol from -100 mV to +100 mV over 500 ms preceded by a -100 mV step for 200 ms; the holding potential was -60 mV, and this protocol was applied once every 2 10 HEPES, 5 Na-EGTA, 3 NaATP, and 0.5 NaGTP (pH 7.25). After cells were voltageclamped in the conventional whole-cell configuration the currents were recorded using a protocol starting with a step to -100 mV for 50 ms then ramp up to +100 mV over 200 ms and was applied every 2 seconds; the holding potential was -40 mV. The currents
were measured with an Axopatch 200B amplifier, filtered at 5 kHz, and digitized through Digidata 1440A interface.
Ca V 2.2 electrophysiology
All plasmids with Ca V 2.2 channels and auxiliary subunits in pMT2 vector were purchased from Addgene (Raghib et al., 2001) . interface. Series resistance was partially compensated using the Axopatch circuitry (about 75-80% prediction and correction; 10 μs lag). Offline leak and capacitive current subtraction used P/4 protocol with the leak pulses applied following the test pulses was carried out using the Clampfit 10.6 software (Molecular Devices).
FRET-based monitoring of G αi1 activation
FRET measurements were performed as described earlier . Briefly, HEK cells were co-transfected with the Gβ-2A-cpV-Gγ2-IRES-Gαi1-mTq2 (Addgene, catalogue # 69623) (van Unen et al., 2016) and μOR. Fluorescence was detected using a photomultiplier-based dual-emission system mounted on an inverted Olympus IX-71 microscope equipped with 40X oil objective (numerical aperture 1.3). Excitation light (430 nm) was provided by a DeltaRAM light source (Photon Technology International, PTI). Emission was measured at 480 and 535 nm using two interference filters and a dichroic mirror to separate the two wavelengths. Raw data were analyzed with the
Felix3.2 program (PTI).
Application of solutions and reagents
Coverslips with attached cells were placed in a recording bath (volume ~200 μL) which was continually perfused with fresh extracellular solution at a flow rate of ~3-4 ml/min from gravity-fed reservoirs, and viewed using an Olympus IX-51 inverted microscope.
Pregeneolone sulfate (PregS) was purchased from Sigma, DAMGO and Herkinorin were purchased from Abcam, PZM21 from MedChem Express, and TRV130 from Adooq Bioscience. DAMGO and morphine stock were dissolved in H 2 O. PregS, Herkinorin, PZM21 and TRV130 were dissolved in DMSO. All stock dilutions were prepared on the day of the experiment.
Statistics
Data analysis was performed in Excel and Microcal Origin. The normality of the data was verified with the Kolmogorov-Smirnov test. Data were analyzed with t-test, or
Analysis of variance with Bonferroni post-hoc test *p<0.05, **p<0.01, ***p<0.005. Data are displayed as box-whisker and scatter plots for most figures; mean values are described in the results section for most measurements. Changes in the relative fluorescence ratio according to the following formula: ΔR n / ΔR 1 = 100(R n − R 0 )/ (R 1 − R 0 ) normalized to the first pulse of PregS (PS1). Normalized responses of FRET signals evoked by the applications of 10 nM DAMGO (n=4), 100 nM DAMGO (n=8) and 1 μM DAMGO (n=36), 1 μM TRV130 (n=6), 1 μM PZM21 (n=8), 1 μM Herkinorin (n=5) and 10 μM Herkinorin (n=8). All fluorescence ratio traces were normalized to the ratio level before the application of the stimulus. 
